The potential of muscarinic M
M1 receptor
M4 receptor
acetylcholine
cognition
cognitive impairment associated with schizophrenia
muscarinic
schizophrenia
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2024
2024
Historique:
received:
23
04
2024
accepted:
03
09
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Cognitive impairment is a core symptom of schizophrenia and a major determinant of poor long-term functional outcomes. Despite considerable efforts, we do not yet have any approved pharmacological treatments for cognitive impairment associated with schizophrenia (CIAS). A combination of advances in pre-clinical research and recent clinical trial findings have led to a resurgence of interest in the cognition-enhancing potential of novel muscarinic acetylcholine receptor (mAChR) agonists in schizophrenia. This article provides an overview of the scientific rationale for targeting M
Identifiants
pubmed: 39483736
doi: 10.3389/fpsyt.2024.1421554
pmc: PMC11525114
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1421554Informations de copyright
Copyright © 2024 Yohn, Harvey, Brannan and Horan.
Déclaration de conflit d'intérêts
SY and WH are employees of Karuna Therapeutics, a Bristol Myers Squibb Company, supplier of KarXT. SB is a consultant of Karuna Therapeutics, a Bristol Myers Squibb Company, supplier of KarXT. PH is a consultant for Alkermes, Boehringer Ingelheim, Karuna Therapeutics, a Bristol Myers Squibb Company, Merck, Minerva Neuroscience, and Sunovion/DSP and has received royalties from WCG.